HBK Sorce Advisory’s Capricor Therapeutics CAPR Stock Holding History

HBK Sorce Advisory’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.94M	Buy	225,256 +2,180	+1%	+$24.1K	0.04%	160
2026 Q2	$877K	Buy	223,076 +18,239	+9%	+$553K	0.02%	282
2026 Q1	$6.22M	Buy	204,837 +1,132	+0.6%	+$30.2K	0.12%	61
2025 Q4	$5.04M	Buy	203,705 +33,128	+19%	+$433K	0.12%	77
2025 Q3	$1.14M	Buy	170,577 +42,951	+34%	+$316K	0.03%	211
2025 Q2	$1.27M	Buy	127,626 +77,782	+156%	+$822K	0.03%	189
2025 Q1	$473K	Buy	+49,844	New	+$692K	0.01%	352

Other funds holding CAPR

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Black Diamond Financial Towson, Maryland $1.18B AUM 15.24% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

HBK Sorce Advisory's CAPR Position: Q3 2026 in Review

HBK Sorce Advisory increased its Capricor Therapeutics (CAPR) stake by 0.98% in Q3 2026, buying an estimated $24.1K and bringing the position to 225,256 shares worth $1.94M. The position accounts for 0.04% of the portfolio, ranked #160.

HBK Sorce Advisory first reported a position in CAPR in Q1 2025 and has held it in 7 quarters since. The position peaked at $6.22M in Q1 2026. 52 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

HBK Sorce Advisory held 225,256 shares of Capricor Therapeutics worth $1.94M as of Q3 2026.
HBK Sorce Advisory bought 2,180 Capricor Therapeutics shares in Q3 2026, an estimated $24.1K.
Capricor Therapeutics made up 0.04% of HBK Sorce Advisory's portfolio in Q3 2026, its #160 holding.
HBK Sorce Advisory first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 7 quarters since.
HBK Sorce Advisory's Capricor Therapeutics position peaked at $6.22M in Q1 2026.
52 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on HBK Sorce Advisory's 13F filing for Q3 2026, filed 6 Nov 2026.